Everolimus and Capecitabine in Patients With Advanced Malignancy
Status:
Unknown status
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
In the investigators study the investigators combine everolimus, administrated twice daily at
a fixed total dose of 10 mg continuously with capecitabine administered bid for 14 days
followed by 7 days rest. In this study, capecitabine will be dose escalated.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)